RecruitingPhase 1Phase 2NCT06193902

LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.

A Phase I/IIa Open-label Dose Escalation Trial Evaluating the Safety and Preliminary Efficacy of LEU011 in Subjects With Relapsed/Refractory Solid Tumours

Sponsor

Leucid Bio

Enrollment

17 participants

Start Date

Nov 13, 2023

Study Type

INTERVENTIONAL

Conditions

Tumor, Solid

Summary

This is a dose-escalation open-label Phase 1/2a study. The purpose of this first-in-human study is to assess the safety and tolerability of LEU011 (autologous CAR T cells targeting NKG2D ligands) in patients with solid tumours.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called LEU011 for people with tumor, solid. The study is currently recruiting participants at 2 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.